Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload

恩帕吉菲 医学 心力衰竭 容量过载 利尿剂 射血分数 射血分数保留的心力衰竭 心脏病学 血管内容积状态 内科学 安慰剂 糖尿病 血流动力学 2型糖尿病 内分泌学 替代医学 病理
作者
Milton Packer,Stefan D. Anker,Javed Butler,Gerasimos Filippatos,João Pedro Ferreira,Stuart J. Pocock,Naveed Sattar,Martina Brueckmann,Waheed Jamal,Daniel Cotton,Tomoko Iwata,Faı̈ez Zannad
出处
期刊:Journal of the American College of Cardiology [Elsevier]
卷期号:77 (11): 1381-1392 被引量:120
标识
DOI:10.1016/j.jacc.2021.01.033
摘要

Investigators have hypothesized that sodium-glucose cotransporter 2 (SGLT2) inhibitors exert diuretic effects that contribute to their ability to reduce serious heart failure events, and this action is particularly important in patients with fluid retention. This study sought to evaluate the effects of the SGLT2 inhibitor empagliflozin on symptoms, health status, and major heart failure outcomes in patients with and without recent volume overload. This double-blind randomized trial compared the effects of empagliflozin and placebo in 3,730 patients with heart failure and a reduced ejection fraction, with or without diabetes. Approximately 40% of the patients had volume overload in the 4 weeks before study enrollment. Patients with recent volume overload were more likely to have been hospitalized for heart failure and to have received an intravenous diuretic agent in an outpatient setting in the previous 12 months, and to experience a heart failure event following randomization, even though they were more likely to be treated with high doses of a loop diuretic agent as an outpatient (all p < 0.001). When compared with placebo, empagliflozin reduced the composite risk of cardiovascular death or hospitalization for heart failure, decreased total hospitalizations for heart failure, and improved health status and functional class. Yet despite the predisposition of patients with recent volume overload to fluid retention, the magnitude of these benefits (even after 1 month of treatment) was not more marked in patients with recent volume overload (interaction p values > 0.05). Changes in body weight, hematocrit, and natriuretic peptides (each potentially indicative of a diuretic action of SGLT2 inhibitors) did not track each other closely in their time course or in individual patients. Taken together, study findings do not support a dominant role of diuresis in mediating the physiological changes or clinical benefits of SGLT2 inhibitors on the course of heart failure in patients with a reduced ejection fraction. (EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction [EMPEROR-Reduced]; NCT03057977)
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
壮观秋关注了科研通微信公众号
刚刚
彬子发布了新的文献求助10
刚刚
2秒前
2秒前
纪容完成签到 ,获得积分10
2秒前
丘比特应助科研通管家采纳,获得10
2秒前
ding应助科研通管家采纳,获得10
2秒前
司空大有应助科研通管家采纳,获得10
2秒前
所所应助科研通管家采纳,获得10
3秒前
stuffmatter应助科研通管家采纳,获得30
3秒前
orixero应助科研通管家采纳,获得10
3秒前
英姑应助科研通管家采纳,获得10
3秒前
赘婿应助科研通管家采纳,获得30
3秒前
新小pi应助科研通管家采纳,获得10
3秒前
3秒前
3秒前
3秒前
3秒前
4秒前
慕青应助yh采纳,获得10
4秒前
5秒前
李健应助笑点低蜜蜂采纳,获得10
5秒前
MO完成签到,获得积分20
6秒前
mu完成签到,获得积分20
6秒前
搜集达人应助海之蓝采纳,获得10
6秒前
7秒前
7秒前
脑洞疼应助四憙采纳,获得10
7秒前
cly3397完成签到,获得积分10
8秒前
Onesimus发布了新的文献求助10
8秒前
8秒前
鱼儿123发布了新的文献求助10
8秒前
Shiki完成签到 ,获得积分10
8秒前
8秒前
lalahulala完成签到,获得积分10
9秒前
9秒前
mu发布了新的文献求助10
9秒前
www完成签到 ,获得积分10
9秒前
9秒前
追寻砖家完成签到 ,获得积分10
9秒前
高分求助中
Sustainability in Tides Chemistry 1500
Handbook of the Mammals of the World – Volume 3: Primates 805
Ethnicities: Media, Health, and Coping 800
Gerard de Lairesse : an artist between stage and studio 500
Digging and Dealing in Eighteenth-Century Rome 500
Queer Politics in Times of New Authoritarianisms: Popular Culture in South Asia 500
Manual of Sewer Condition Classification 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3069006
求助须知:如何正确求助?哪些是违规求助? 2722831
关于积分的说明 7479538
捐赠科研通 2369753
什么是DOI,文献DOI怎么找? 1256697
科研通“疑难数据库(出版商)”最低求助积分说明 609645
版权声明 596839